Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.

摘要: BACKGROUND Locally advanced adenocarcinoma of the esophagus (EAC) and squamous cell carcinoma (ESCC) result in a worse prognosis. Neoadjuvant treatment improves survival, however, only for responders. The transmembrane glycoprotein podoplanin is overexpressed carcinomas, miRNA-363 associated to its regulation head neck cancer. AIM To predict therapy response prognosis markers, targets novel therapies would individualize treatments leading more favourable outcomes. METHODS Expression protein has been visualized by immunohistochemistry surgical specimens 195 esophageal cancer patients who underwent transthoracic esophagectomy: 90 ESCC 105 EAC with clinical T2-3, Nx, M0. One hundred six received neoadjuvant chemoradiation. RNA was extracted from paraffin-embedded tissue, quantified real-time TaqMan-real-time-PCR. D2-40 mab staining > 5% scored as high expression (HPE). We related histopathologic after clinicopathological characteristics, such histological tumor type, survival rate or category. RESULTS confirmed membrane-bound patients. 26% showed HPE 5%. In addition, absence (only 2% HPE) shown. Lower detected resection-specimen 58 (RTx/CTx) treatment, 11% HPE, compared 50% 32 non-pretreated primary surgery patients, P = 0.0001. This difference comparing pre-treatment biopsies matching post-treatment specimens, < 0.001. Podoplanin identified prognostic marker that without treatment. Low (0-5%) better 0.013. post-transcriptional miRNA-363. At cut-off value miR-363 7, lower correlated tissue Therefore, 7 had than expressing ≥ 0.049. CONCLUSION Analysis molecular process leads decrease during may provide markers improve targeted ESCC.